BiBBInstruments Secures U.S. Patent for EndoDrill®
BiBBInstruments has achieved a significant milestone with the U.S. patent approval for its EndoDrill® series, paving the way for commercialization.
Sammanfattning
BiBBInstruments has received a Notice of Allowance for its U.S. patent application, providing broad protection for the EndoDrill® series. This is a key step towards commercialization in the U.S.
BiBBInstruments, a pioneer in cancer diagnostics, has marked a significant milestone with the receipt of a Notice of Allowance for its U.S. patent application 17/283,928. This patent is a vital component of BiBB's Patent Family 1 and offers extensive protection for its innovative EndoDrill® product series in the U.S. market. The EndoDrill® series, known for its precision in obtaining high-quality tissue samples, is set to revolutionize the diagnosis of several severe cancers, including those affecting the stomach, pancreas, liver, lung, and bladder.
The approval of this patent is timely, aligning with BiBB's recent Letter of Intent with TaeWoong Medical USA for the distribution of EndoDrill® GI. This strategic move underscores BiBB's commitment to expanding its footprint in the U.S. market, a crucial step following its 510(k) clearance from the US FDA in 2023 and CE marking in early 2024.
BiBBInstruments' robust patent portfolio, with granted patents in major markets such as Europe, Japan, India, and China, positions the company strongly in the global market for ultrasound-guided endoscopic biopsy instruments. The EndoDrill® system, being the first powered endoscopic biopsy system cleared in both the U.S. and Europe, offers a competitive edge in this fast-growing sector.
Given these developments, investors might consider a 'buy' position. The company's strategic partnerships and expanding patent protections suggest a promising growth trajectory. However, as with any investment, potential investors should consider market conditions and consult with financial advisors.
Källa
Sammanfattning
BiBB has received a Notice of Allowance for a U.S. patent application, part of its Patent Family 1, which offers broad protection for its EndoDrill® product series in the U.S. The company has three international patent applications for EndoDrill® in the national/regional phase, with patents already granted in the U.S., Europe, Japan, India, and China. The remaining applications are being pursued for global protection of the powered endoscopic biopsy instrument. CEO Fredrik Lindblad highlights the importance of the U.S. patent approval as BiBB moves towards commercialization in the U.S., following a recent distribution agreement with TaeWoong Medical USA. BiBBInstruments AB, founded in 2013, develops and manufactures the EndoDrill®, a line of endoscopic biopsy instruments aimed at improving cancer diagnosis. The company has received FDA clearance and CE marking for its products, making EndoDrill® the first cleared powered endoscopic biopsy system in the U.S. and Europe. BiBBInstruments is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.
